Orchid pharma Limited has announced a significant development in its ongoing merger proceedings, informing stock exchanges that the National Company Law Tribunal (NCLT) order on its amalgamation scheme has been reserved for formal pronouncement.

NCLT Order Status Update

The company filed an official communication on March 18, 2026, under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The update pertains to the scheme of amalgamation between Dhanuka Laboratories Limited and Orchid Pharma Limited, involving their respective shareholders and creditors.

Regulatory Compliance and Next Steps

The notification was made in compliance with SEBI Master Circular dated January 30, 2026, and represents a continuation of earlier intimations regarding the merger petition pending with the NCLT. The company has committed to providing further updates to stock exchanges and making information available on its website upon receiving the copy of the NCLT order.

Corporate Structure Details

Under the proposed scheme, Dhanuka Laboratories Limited will serve as the amalgamating company, while Orchid Pharma Limited will be the amalgamated company. The arrangement encompasses both companies' shareholders and creditors, indicating a comprehensive corporate restructuring initiative.

The formal pronouncement of the NCLT order will mark a crucial milestone in the amalgamation process, with stakeholders awaiting the tribunal's decision on this corporate restructuring proposal.

Orchid Pharma Limited has announced an analysts and investors earnings call to discuss its financial results for the third quarter of Financial Year 2025-26, ended December 31, 2025. The call is scheduled for February 12, 2026 at 4:30 PM IST and will be hosted by Systematix Institutional Equities.

Regulatory Compliance and Announcement Details

The company made this announcement on February 06, 2026, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation also references SEBI Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026.

Management Participation

The earnings call will feature key members of the company's leadership team who will discuss the Q3FY26 financial performance:

Call Access Information

Systematix Institutional Equities has provided multiple dial-in options for participants:

Participants can also access the call through DiamondPass™, a premium service that allows direct connection without waiting for an operator.

Additional Information

The company has indicated that the earnings call information will be hosted on its official website at www.orchidpharma.com . The announcement includes a note that the schedule may undergo changes due to exigencies on the part of analysts, investors, or the company. For additional information regarding the call, participants can contact Vishal Manchanda, Equity Research Analyst, or Mrunal Pawar, VP & Group Head - Corporate Access & Corporate Communication at Systematix Institutional Equities.